Seeking Alpha

ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to ...

Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its progress ...
Nasdaq

ProPhase Labs, Inc. (PRPH) Soars 9.1%: Is Further Upside Left in the Stock?

ProPhase Labs, Inc. PRPH shares rallied 9.1% in the last trading session to close at $14.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Business Insider

ProPhase Labs, Inc. Announces Commencement of Tender Offer to Repurchase Up to 1.7 Million Shares of Its Common Stock at Price of $2.30 Per Share

DOYLESTOWN, Pa., Nov. 20, 2017 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (www.ProPhaseLabs.com), a diversified natural health medical science company (the “Company” or “ProPhase”), today ...
Seeking Alpha

ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Garden City, NY, Feb. 06, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today provided an update ...